Research progress of immune checkpoint Tim-3 in tumor immunology

doi:10.3877/cma.j.issn.2095-9141.2016.02.013

Abstract

Abstract:

The discovery of immune checkpoints has become an interesting topic in tumor immunotherapy area. This aticle discussed its function of tumor inhibition from three aspects through researches of immune checkpoint Tim-3. Firstly, play a role through combination of the different ligands. Secondly, negatively regulate the CD4⁺T/CD8⁺T/NK cells. Thirdly, immunotherapy Aimed at Tim-3. Declare that Tim-3 makes the contribution to tumor immune escape by specific binding with different ligands to the inhibitions both inherent immunity and adaptive immunity. This state of Tim-3 specificity of immunosuppressive is aimed at providing the new way and basis for tageted immunologic therapy.

Key words: Tim-3, Tumor, Immune escape, Immunologic therapy

Yuanyuan Deng, Yimin Fan. Research progress of immune checkpoint Tim-3 in tumor immunology[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2016, 02(02): 112-115.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2016.02.013

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2016/V02/I02/112

References 35

[1]	Le Mercier I,Lines JL,Noelle RJ. Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators[J]. Front Immunol, 2015, 6: 418.
[2]	Monney L,Sabatos CA,Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease[J]. Nature, 2002, 415(6871): 536-541.
[3]	Sabatos CA,Chakravarti S,Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance[J]. Nat Immunol, 2003, 4(11): 1102-1110.
[4]	Cao E,Zang X,Ramagopal UA, et al. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface[J]. Immunity, 2007, 26(3): 311-321.
[5]	Santiago C,Ballesteros A,Tami C, et al. Structures of T cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the Tim receptor family[J]. Immunity, 2007, 26(3): 299-310.
[6]	DeKruyff RH,Bu X,Ballesteros A, et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells[J]. J Immunol, 2010, 184(4): 1918-1930.
[7]	Zhu C,Anderson AC,Kuchroo VK. Tim-3 and Its Regulatory Role in Immune Responses[J]. Curr Top Microbiol Immunol, 2011, 350: 1-15.
[8]	Rodriguez-Manzanet R,DeKrayff R,Kuchroo VK, et al. The costimulatory role of Tim molecules[J]. Immunol Rev, 2009, 229(1): 259-270.
[9]	Cao E,Zang X,Ramagopal UA, et al. T Cell Immunoglobulin Mucin-3 Crystal Structure Reveals a Galectin-9-Independent Ligand-Binding Surface[J]. Immunity, 2007, 26(3):311-321.
[10]	DeKruyff RH,Bu X,Ballesteros A, et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells[J]. J Immunol, 2010, 184(4): 1918-1930.
[11]	Nakayama M,Akiba H,Takeda K, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation[J]. Blood, 2009, 113(16): 3821-3830.
[12]	Chabtini L,Mfarrej B,Mounayar M, et al. Tim-3 regulates innate immune cells to induce fetomaternal tolerance[J]. J Immunol, 2012, 190(1): 88-96.
[13]	Huang YH,Zhu C,Kondo Y, et al. CEACAM1 regulates Tim-3-mediated tolerance and exhaustion[J]. Nature, 2015, 517(7534): 386-390.
[14]	Japp AS,Kursunel MA,Meier S, et al. Dysfunction of PSA-specific CD8⁺ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression[J]. Cancer Immunol Immunother, 2015, 64(11): 1487-1494.
[15]	Cai C,Xu YF,Wu ZJ, et al. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma[J]. World J Urol, 2016, 34(4): 561-567.
[16]	Kang CW,Dutta A,Chang LY, et al. Apoptosis of tumor infiltrating effector Tim-3⁺CD8⁺ T cells in colon cancer[J]. Sci Rep, 2015, 5: 15659.
[17]	Heon EK,Wulan H,Macdonald LP, et al. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer[J]. Biochem Biophys Res Commun, 2015, 464(1): 360-366.
[18]	Yang ZZ,Grote DM,Ziesmer SC, et al. IL-12 upregulates Tim-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma[J]. J Clin Invest, 2012, 122(4): 1271-1282.
[19]	Zeijlemaker W,Kelder A,Oussoren-Brockhoff YJ, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia[J]. Leukemia, 2016, 30(2): 439-446.
[20]	Li C,Chen X,Yu X, et al. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification[J]. Int J Clin Exp Pathol, 2014, 7(10): 6880-6888.
[21]	Kong Y,Zhang J,Claxton DF, et al. PD-1(hi)Tim-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation[J]. Blood Cancer, 2015, 5: e330.
[22]	Prokhorov A,Gibbs BF,Bardelli M, et al. The immune receptor Tim-3 mediates activation of PI3 kinase/mTOR and HIF-1 pathways in human myeloid leukaemia cells[J]. Int J Biochem Cell Biol, 2015, 59: 11-20.
[23]	Gao L,Yu S,Zhang X. Hypothesis: Tim-3/Galectin-9, A New Pathway for Leukemia Stem Cells Survival by Promoting Expansion of Myeloid-Derived Suppressor Cells and Differentiating into Tumor-Associated Macrophages[J]. Cell Biochem Biophys, 2014, 70(1): 273-277.
[24]	Huang X,Bai X,Cao Y, et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion[J]. J Exp Med, 2010, 207(3): 505-2010.
[25]	Ndhlovu LC,Lopez-Vergès S,Barbour JD, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity[J]. Blood, 2012, 119(16): 3734-3743.
[26]	Gallois A,Silva I,Osman I, et al. Reversal of natural killer cell exhaustion by Tim-3 blockade[J]. Oncoimmunology, 2014, 3(12): e946365.
[27]	Xu L,Huang Y,Tan L, et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma[J]. Int Immunopharmacol, 2015, 29(2): 635-641.
[28]	Komita H,Koido S,Hayashi K, et al. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors[J]. Oncol Rep, 2015, 34(4): 2099-2105.
[29]	Wang Z,Zhu J,Gu H, et al. The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer[J]. Immunol Invest, 2015, 44(6): 578-589.
[30]	Folgiero V,Cifaldi L,Pira GL, et al. Tim-3/Gal-9 interaction induces IFN-γ-dependent IDO1 expression in acute myeloid leukemia blast cells[J]. J Hematol Oncol, 2015, 8(1): 36.
[31]	Melero I,Hervas-Stubbs S,Glennie M, et al. Immunos Timulatory monoclonal antibodies for cancer therapy[J]. Nat Rev Cancer, 2007, 7(2): 95-106.
[32]	Melero I,Grimaldi AM,Perez-Gracia JL, et al. Clinical development of immunosTimulatory monoclonal antibodies and opportunities for combination[J]. Clini Cancer Res, 2013, 19(5): 997-1008.
[33]	Schreiber RD,Old LJ,Smyth MJ. Cancer immunoediting: integrating immunity′s roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-1570.
[34]	Desrichard A,Snyder A,Chan TA. Cancer Neoantigens and Applications for Immunotherapy[J]. Clin Cancer Res, 2016, 22(4): 807-812.
[35]	Sathyanarayanan V,Neelapu SS. Cancer immunotherapy: Strategies for personalization and combinatorial approaches[J]. Mol Oncol, 2015, 9(10): 2043-2053.

Please choose a citation manager

Content to export